

Office for Human Research Protections The Tower Building 1101 Wootton Parkway, Suite 200 Rockville, Maryland 20852

Telephone: 240-453-8298 FAX: 240-453-6909 E-mail: pmcneilly@osophs.dhhs.gov

February 17, 2006

Tecla Mickoseff CEO Harbor-UCLA Medical Center 1000 West Carson Street Torrance, CA 90509

RE: Human Research Subject Protections Under Multiple Project Assurance M-1301 and Federalwide Assurance FWA-2334

Research Project: Phase I/II Trial: The Safety and Immunogenicity of Live-

Attenuated Varicella Vaccine (Varivax) in HIV-Infected Children

Project Number: ACTG #265

Principal Investigator:

Research Project: Phase I Trial: Safety and Effectiveness of Four Anti-HIV Drug

Combinations in HIV-Infected Children and Teens

Project Number: ACTG #377

Principal Investigator: Margaret Keller, M.D.

Dear Ms. Mickoseff:

The Office for Human Research Protections (OHRP) has reviewed the Harbor-UCLA Medical Center's (HUMC) July 14, 2005 response to OHRP's June 9, 2005 letter regarding indications of possible noncompliance with Department of Health and Human Services (HHS) regulations for the protection of human research subjects (45 CFR part 46) involving the above-referenced research.

Based upon its review, OHRP finds that HUMC has addressed the concerns raised in OHRP's June 9, 2005 letter. In particular, OHRP notes the HUMC report stated that ACTG #265 did not include wards of the state, and ACTG #377 included wards of the state but was determined by the institutional review board at its December 9, 1997 meeting to fall under HHS regulations at 45 CFR 46.405. As a result, there should be no need for further involvement of OHRP in this matter.

Page 2 of 2 Harbor-UCLA Medical Center – Tecla Mickoseff February 17, 2006

OHRP appreciates the continued commitment of your institution to the protection of human research subjects. Please do not hesitate to contact me should you have any questions.

Sincerely,

Patrick J. McNeilly, Ph.D. Compliance Oversight Coordinator Division of Compliance Oversight

cc: Dr. Stewart A. Laidlaw, Director, Compliance and Regulatory Affairs, HUMC

Dr. Kenneth R. Huff, Chairperson, John F. Wolf Human Subjects Committee IRB #1

Dr. Michael Smith, Chairperson, John F. Wolf Human Subjects Committee IRB #2 Commissioner, FDA

Dr. David Lepay, FDA

Dr. Lana Skirboll, NIH

Dr. Anthony Fauci, NIH

Dr. Edmund C. Tramont, NIH

Ms. Donna Marchigiani, NIH

Dr. Robinsue Frohboese, OCR

Dr. Bernard Schwetz, OHRP

Dr. Melody H. Lin, OHRP

Dr. Michael Carome, OHRP

Dr. Kristina Borror, OHRP

Ms. Shirley Hicks, OHRP

Dr. Irene Stith-Coleman, OHRP

Ms. Patricia El-Hinnawy, OHRP

Ms. Janet Fant, OHRP